

identification (Minimum 3 key characteristics)			
Final identification	✓		0 0.5 1 1.5 (2)

Susceptibility report	EXPECTED REPORT			PARTICIPANT REPORT		MARK	TYPE OF ERROR
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	10 marks	Error
Co-trimoxazole	≥16	≤2/38	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Levofloxacin	≥21	≤0.5	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Piperacillin-Tazobactam	≥21	≤16	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Ertapenem	≥22	≤0.5	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME
Meropenem	≥23	≤1.0	Susceptible	✓		-1 0 1 (2)	mE/ ME/ VME

DECEMBER 2020 / SEROLOGY

Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

	Parameter	Your Result	Your Value	Intended Result			Method	Robust Mean	Robust SD	Range (mg/L)	Z & Z' score	Max Marks	Your Score
SE1	RA	Negative	<10 IU/mL	Negative			Nephelometry (n-123)	NA	NA	NA	NA	2	2
SE2	WIDAL*	Correct	Correct	STO Negative	STH Negative	Interpretation Negative	Tube agglutination	Not Applicable				2	2
SE3	CRP	Positive	48.74 mg/L	Positive			Nephelometry (n-107)	57.6127	11.0401	0.5 to 90.0	-0.8	2	2

RA: Rheumatoid Factor, CRP: C-reactive Protein. NA: Not Applicable. *Expected value is determined by the Proficiency Testing Provider (PTP).


Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID:

M 0 6 3 0


SM1	SM2	SM3	CU1	CU2	CU3	SE1	SE2	SE3	Marks obtained	
4	4	4	14	13	17	2	2	2	62	92.5%
4	4	4	15	17	17	2	2	2	Maximum marks = 67	



Dr. Rani Diana Sahni
Scientific Co-ordinator



Dr. John A Jude Prakash
Quality Manager



Dr. V. Balaji
PT Co-ordinator

Report Dispatch Date: 28.02.2021

***** End of Report *****